IMAGENT
LOE Approachingdimyristoyl lecithin; perflexane
NDAINTRAVENOUSINJECTABLE
Approved
May 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMAGENT is an intravenous injectable diagnostic agent containing dimyristoyl lecithin and perflexane, approved in 2002 for use as an ultrasound contrast medium. It enhances visualization of cardiac structures and blood flow during echocardiography and other ultrasound procedures. The product functions as a microbubble contrast agent that reflects ultrasound waves to improve image quality.
LOE Approaching
LOE is approaching for this 2002-approved product, signaling reduced team investment and potential consolidation within marketing and sales functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings for IMAGENT reflects its mature, late-stage lifecycle and approaching loss of exclusivity. Roles on this product are primarily maintenance-focused, offering limited career growth or skill-building opportunities compared to growth-stage assets.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.